Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2million in Q2 2021, reflecting growth of 15% over the previous quarter
- ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2million in Q2 2021, reflecting growth of 15% over the previous quarter
Net loss in Q2 2021 decreased by $10.4million (32%), as compared to Q2 2020, during the height of the COVID-19 impact on ZILRETTA sales
BURLINGTON, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June30, 2021. - Net sales of ZILRETTA were $28.2million and $15.5million for the three months ended June30, 2021 and 2020, respectively.
- Loss per share for the second quarter of 2021 was $0.44, compared to $0.76 for the same period of 2020.
- Research and development expenses were $12.7million and $12.5million for the three months ended June30, 2021 and 2020, respectively.